Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The OPTIENOX-PCI is a single-center, prospective, randomized, open-label, controlled study,
which is designed to assess the anticoagulation profile of: 1) High-dose (0.75 mg/kg) vs.
Standard-dose (0.5 mg/kg) enoxaparin; 2) Staged-dose (0.5+0.25 mg/kg) vs. Single-dose (0.75
mg/kg) enoxaparin in about 376 patients who plan to undergo elective trans-radial coronary
angiography (CAG) with or without subsequent percutaneous coronary intervention (PCI).